APR 03, 2018 8:27 PM PDT

Two-Drug Strategy for Non-Small Cell Lung Cancer (NSCLC)

WRITTEN BY: Nouran Amin

According to the National Cancer Institute, lung cancer is the most common cause of cancer death for both men and women in the U.S. More specifically, non-small cell lung cancer (NSCLC) encompasses 85% of all lung cancers.

Investigators seeking new treatment options for patients of lung cancer have found a combination of drugs that are effective for NSCLC specifically. These drugs target epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF), the targeting works to effectively inhibit the cancer from using TNF as way to escape and allowing the cancer to be sensitive to the EGFR treatment.

"There has been a tremendous effort over the past several years to block EGFR as a treatment for lung cancer, but this therapy only works in a small subset of patients. The cancer fights back with a bypass pathway," explains lead researcher Dr. Amyn Habib with the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern as well as a staff physician at the Dallas Veterans Affairs Medical Center. "Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients.” These research findings stem from the same combination of drug treatments that were found to be successful in a glioblastoma mouse model.Bottom Rows: Tumors treated w/ two-drug strategy. Top Rows: Tumors left untreated or w/ a single treatment. Credit: UT Southwestern via Science Daily

Furthermore, these anti-EGFR/TNF two-strategy drugs were found to be well tolerated and with few side effects which was because they worked to target specific molecules within cancer cells. Thus, anti-EGFR/TNF drugs are more advantageous than traditional chemotherapeutic treatments which have unpleasant side-effects on a patient.

Investigators will continue their research for a phase 2 clinical trial of using the two-drug strategy; which has already been approved by the FDA. The prospective clinical studies are being planned to test the two-drug treatment in lung cancer patients as well as glioblastomas. "If this strategy is effective, then it might be broadly applicable not only against lung cancer but also against other cancers that express EGFR, which include brain, colon, and head and neck cancers," says lead clinical studies leader Dr. Gerber, an Associate Professor of Internal Medicine and Clinical Sciences.

Until recently, EGFR inhibitors were studied to be effective at treating a small percentage of non-small cell lung cancers that have a variant form of EGFR. However, with two-drug strategy, treatment could be effective for all forms of non-small cell lung cancers.

The research was published in the Journal of Clinical Investigation.

Source: Journal of Clinical Investigation, Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 11, 2020
Cancer
APR 11, 2020
The Mice Make the Difference in CAR-T Studies
It is quite common in cancer therapies to see a drug or treatment that has been around for decades. New drugs are hard t ...
APR 21, 2020
Neuroscience
APR 21, 2020
Considerations for Lab Managers in Choosing a Microplate Reader
In today's high-tech, digitized laboratory environments, nobody pays very much attention to the humble plastic micro ...
MAY 07, 2020
Cancer
MAY 07, 2020
Yet Another Cancer Linked Tyrosine Kinase
In a cell, there are tens of thousands of individual components. Each component has a specific activity or role that the ...
MAY 12, 2020
Drug Discovery & Development
MAY 12, 2020
Does Herbal Drink from Madagascar Cure COVID-19?
Andry Rajoelina, the president of Madagascar, an island off the coast of Southern Africa, has made claims that his count ...
MAY 21, 2020
Cancer
MAY 21, 2020
A New Player in the Regulation of Cancer's Microenvironment
Breast cancer is one of the most common cancers in the world.  Triple-negative breast cancer (TNBC) is a sub-type o ...
MAY 12, 2020
Drug Discovery & Development
MAY 12, 2020
Novel Drug Approved for Non-Small Cell Lung Cancer
The US Food and Drug Administration (FDA) recently approved a therapeutic for treating metastatic non-small cell lung ca ...
Loading Comments...